葵花药业
(002737)
| 流通市值：104.24亿 | | | 总市值：104.24亿 |
| 流通股本：5.84亿 | | | 总股本：5.84亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,966,906,461.88 | 2,527,602,096.82 | 1,518,181,069.65 | 5,700,286,745.9 |
| 营业收入 | 2,966,906,461.88 | 2,527,602,096.82 | 1,518,181,069.65 | 5,700,286,745.9 |
| 二、营业总成本 | 2,354,275,676.31 | 1,919,138,011.84 | 1,198,310,855.92 | 4,496,121,261.21 |
| 营业成本 | 1,417,182,527.64 | 1,119,651,646.08 | 656,365,307.85 | 2,491,559,192.4 |
| 税金及附加 | 38,708,788.97 | 30,209,135.09 | 16,119,060.52 | 68,504,508.76 |
| 销售费用 | 540,060,782.14 | 517,723,975.72 | 395,103,030.63 | 1,366,528,519.93 |
| 管理费用 | 300,622,453.51 | 221,082,583.85 | 118,842,698.14 | 472,844,801.3 |
| 研发费用 | 79,433,350.55 | 51,434,495.15 | 22,993,910.9 | 128,647,229.2 |
| 财务费用 | -21,732,226.5 | -20,963,824.05 | -11,113,152.12 | -31,962,990.38 |
| 其中:利息费用 | 1,619,717.18 | 354,115.8 | 203,493.32 | 5,965,267.65 |
| 其中:利息收入 | 24,133,291.74 | 21,712,149.32 | 11,099,150.02 | 38,389,670.12 |
| 加:公允价值变动收益 | -3,573,110.59 | -12,288,734.9 | -5,356,166.41 | -16,388,444.95 |
| 加:投资收益 | 12,785,310.25 | 9,230,674.13 | 5,407,601.03 | 46,963,767.59 |
| 资产处置收益 | -185,101.9 | 94.21 | 0 | 3,230,614.33 |
| 资产减值损失(新) | -3,649,650.6 | -992,192.51 | -1,859,231.83 | -978,226.09 |
| 信用减值损失(新) | -21,286,655.05 | -7,920,875.6 | -2,991,054.06 | 2,553,121.34 |
| 其他收益 | 144,473,067.26 | 40,619,319.45 | 23,156,203.91 | 127,279,582.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 741,194,644.94 | 637,112,369.76 | 338,227,566.37 | 1,366,825,899.32 |
| 加:营业外收入 | 5,742,043.3 | 4,481,272.2 | 333,182.95 | 2,594,108.73 |
| 减:营业外支出 | 2,570,616.22 | 1,392,382.4 | 938,184.74 | 14,650,286.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 744,366,072.02 | 640,201,259.56 | 337,622,564.58 | 1,354,769,721.07 |
| 减:所得税费用 | 138,852,550.27 | 123,917,307.96 | 67,319,325.62 | 189,831,101.3 |
| 六、净利润 | 605,513,521.75 | 516,283,951.6 | 270,303,238.96 | 1,164,938,619.77 |
| 持续经营净利润 | 605,513,521.75 | 516,283,951.6 | 270,303,238.96 | 1,164,938,619.77 |
| 归属于母公司股东的净利润 | 586,835,406.5 | 486,332,757.84 | 255,183,288.86 | 1,119,142,042.33 |
| 少数股东损益 | 18,678,115.25 | 29,951,193.76 | 15,119,950.1 | 45,796,577.44 |
| (一)基本每股收益 | 1 | 0.83 | 0.44 | 1.92 |
| (二)稀释每股收益 | 1 | 0.83 | 0.44 | 1.92 |
| 八、其他综合收益 | 120,556.8 | 17,035.2 | 32,760 | -45,864 |
| 归属于母公司股东的其他综合收益 | 84,389.76 | 11,924.64 | 22,932 | -32,104.8 |
| 九、综合收益总额 | 605,634,078.55 | 516,300,986.8 | 270,335,998.96 | 1,164,892,755.77 |
| 归属于母公司股东的综合收益总额 | 586,919,796.26 | 486,344,682.48 | 255,206,220.86 | 1,119,109,937.53 |
| 归属于少数股东的综合收益总额 | 18,714,282.29 | 29,956,304.32 | 15,129,778.1 | 45,782,818.24 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |